Bosnia and Herzegovina vs Lebanon: Share of E. coli infections resistant to cephalosporins
Bosnia and Herzegovina
26.8%
in 2022
Lebanon
37.2%
in 2022
Bosnia and Herzegovina rank
25th
Lebanon rank
22nd
Share of E. coli infections resistant to cephalosporins over time
- Bosnia and Herzegovina
- Lebanon
How they compare
Lebanon currently reports 37.2% against 26.8% in Bosnia and Herzegovina, a difference of 10.4%.
That makes Lebanon's figure about 1.4 times Bosnia and Herzegovina's.
Across all 7 years both countries report, Lebanon has been ahead every year.
Bosnia and Herzegovina ranks 25th and Lebanon ranks 22nd of 46 countries.
Lebanon has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bosnia and Herzegovina | Lebanon | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 22.0% | 50.1% | 28.1% | Lebanon |
| 2020s | 26.4% | 47.9% | 21.5% | Lebanon |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of e. coli infections resistant to cephalosporins, Bosnia and Herzegovina or Lebanon?
- Lebanon, at 37.2% against 26.8% in Bosnia and Herzegovina as of 2022.
- What is the difference in share of e. coli infections resistant to cephalosporins between Bosnia and Herzegovina and Lebanon?
- 10.4%, with Lebanon ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and Lebanon?
- 7 years are reported by both, from 2016 to 2022.
- How do Bosnia and Herzegovina and Lebanon rank globally for share of e. coli infections resistant to cephalosporins?
- Bosnia and Herzegovina ranks 25th and Lebanon ranks 22nd of 46 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of E. coli infections resistant to cephalosporins. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%).